Select Bibliography

Filter by any of these (after searching):

NCCTG-N0147

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 28 items

Adjuvant mFOLFOX6 +/- Cetuxiumab in KRAS Wild Type Patients With Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147.

Alberts, S. R. , Sargent, D. J. , Smyrk, T. C. , Shields, A. F. ... - ASCO - J Clin Oncol - 2010

Abstract - Primary - Primary - GI - NCCTG-N0147

Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147.

Alberts, S. R. , Thibodeau, S. N. , Sargent, D. J. , Mahoney, M. R. ... - ASCO - J Clin Oncol - 2011

Abstract - Secondary - Primary - Correl Sci NOS - NCCTG-N0147

Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147

Huang, Jocelin , Nair, Suresh G. , Mahoney, Michelle R. ... - - Clin Colorectal Cancer - 2014

Manuscript - Primary - Other - GI - NCCTG-N0147

DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147)

Lee, Adam M. , Shi, Qian , Pavey, Emily , Alberts, Steven R. ... - - J Natl Cancer Inst - 2014

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147

Association of micropapillary architecture and high tumor budding with prognosis in patients with stage III colon cancer from a FOLFOX-based adjuvant chemotherapy trial: NCCTG N0147 (Alliance)

Lee, Hee Eun , Shi, Qian , Foster, Nate , Chan, Emily , Gill, Sharlene ... - USCAP - Mod Pathol - 2017

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147

Genetic correlates of therapeutic toxicities of stage III colon cancer (CC) patients treated with adjuvant FOLFOX+/-cetuximab (Alliance NCCTG N0147)

Newcomb, Polly A. , Sun, Wei , Hua, Xinwei , Banbury, Barbara ... - ASCO - J Clin Oncol - 2017

Abstract - Secondary-not-in-original - Primary - PPP - NCCTG-N0147

Predictive polygenic score for outcome after first-line oxaliplatin-based chemotherapy in colorectal cancer patients using supervised principal component analysis

Park, A. , Edelmann, Dominic , Canzian, Federico ... - ESHG - Cancer Epidemiol Biomarkers Prev - 2022

Abstract - Secondary-not-in-original - Primary - PPP - A151904 , NCCTG-9741 , NCCTG-N0147

Predictive polygenic score for outcome after first-line oxaliplatin-based chemotherapy in colorectal cancer patients using supervised principal component analysis

Park, A. , Edelmann, Dominic , Canzian, Federico ... - - Cancer Epidemiol Biomarkers Prev - 2022

Manuscript - Secondary-not-in-original - Primary - PPP - A151904 , NCCTG-N0147 , NCCTG-N9741

Pre-diagnostic physical activity and outcomes in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance)

Phipps, Amanda I. , Shi, Qian , Chan, Emily , Gill, Sharlene ... - ASPO - - 2017

Abstract - Secondary-not-in-original - Primary - GI - NCCTG-N0147

Physical activity and outcomes in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance)

Phipps, Amanda I. , Shi, Qian , Zemla, Tyler J. , Dotan, Efrat ... - - Cancer Epidemiol Biomarkers Prev - 2018

Manuscript - Secondary-not-in-original - Primary - GI - NCCTG-N0147

Association of Tumor-infiltrating Lymphocytes (TILs) with Survival Depends on Primary Tumor Sidedness in Stage III Colon Cancers (NCCTG N0147) [Alliance]

Saberzadeh-Ardestani, B. , Foster, N. R. , Lee, H. E. , Shi, Q. ... - - Ann Oncol - 2022

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147

Tumor infiltrating lymphocytes and tumor budding refine prognostication in patients with low and high risk stage III colon cancers (NCCTG N0147)[Alliance]

Sha, D. , Lee, H. , Foster, N.R. , Shi, Q. , Alberts, S.R. ... - ASCO - J Clin Oncol - 2020

Abstract - Secondary-not-in-original - Primary - GI - NCCTG-N0147

Association study of the let-7 microrna-binding site polymorphism in 3-untranslated region (UTR) of the KRAS gene in stage III colon cancers from adjuvant trial NCCTG N0147

Sha, Dan , Lee, Adam , Shi, Qian , Alberts, Steven R. ... - ASCO - J Clin Oncol - 2012

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147

Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance)

Singh, Preet Paul , Shi, Qian , Foster, Nathan R. , Grothey, Axel ... - - Oncologist - 2016

Manuscript - Secondary-not-in-original - Primary - GI - NCCTG-N0147

Relative Contribution of Clinical and Molecular Features to Outcome Within Low and High Risk T and N Groups in Patients with Stage III Colon Cancers (Alliance)

Sinicrope, Frank A. , Huebner, Luke , Laurent-Puig, Pierre ... - ASCO - JCO - 2019

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147

Prognostic impact of BRAF and KRAS mutations and their relationship to DNA mismatch repair (MMR) status in 2,686 stage III colon cancer patients (pts) treated in a phase III study of adjuvant FOLFOX +/- cetusimab: NCCTG N0147.

Sinicrope, Frank A. , Mahoney, Michelle R. , Smyrk, Thomas C. ... - ASCO - J Clin Oncol - 2012

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147

Association of DNA Mismatch Repair and Mutations in BRAF and KRAS with Survival after Recurrence in Stage III Colon Cancers from Phase III Adjuvant Chemotherapy Trials

Sinicrope, Frank A. , Shi, Qian , Allegra, Carmen J. ... - - JAMA Oncol - 2017

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147

Association of an immunoscore with survival of stage III colon cancer (CC) patients treated with adjuvant FOLFOX (Alliance N0147)

Sinicrope, Frank A. , Shi, Qian , Hermitte, Fabienne , Heying, Erica ... - ASCO - J Clin Oncol - 2017

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147

Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy (NCCTG N0147) (Alliance)

Sinicrope, Frank A. , Shi, Qian , Smyrk, Thomas C. ... - ASCO - J Clin Oncol - 2017

Abstract - Secondary - Primary - Correl Sci NOS - NCCTG-N0147

Association of Adiponectin with Tumor Infiltrating Lymphocytes in Patients with Stage III Colon Cancer Treated in an Adjuvant Chemotherapy Trial (NCCTG N0147, Alliance)

Sinicrope, Frank A. , Shi, Qian , Smyrk, Thomas C. ... - ASCO - J Clin Oncol - 2021

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147

Association Of Tumor Infiltrating Lymphocytes (Tils) With Molecular Subtype And Prognosis In Stage III Colon Cancers From A FOLFOX-Based Adjuvant Chemotherapy Trial: NCCTG N0147 (Alliance)

Sinicrope, Frank A. , Smyrk, Thomas C. , Foster, Nathan R. ... - ASCO - J Clin Oncol - 2016

Abstract - Secondary - Primary - Correl Sci NOS - NCCTG-N0147

Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial.

Sinicrope, Frank A , Shi, Qian , Catteau, Aurelie , Poage, Graham M ... - - JCO Precis Oncol - 2022

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147

Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer

Sinicrope, Frank A , Shi, Qian , Smyrk, Thomas C ... - - JNCI Cancer Spectr - 2021

Manuscript - Secondary-not-in-original - Primary - GI - NCCTG-N0147

Was it worth it (WIWI)? patient satisfaction with clinical trial participation: Results from North Central Cancer Treatment Group (NCCTG) Phase III Trial N0147

Sloan, J. A. , Mahoney, M. R. , Sargent, D. J. , Hubbard, J. M. ... - ASCO - J Clin Oncol - 2011

Abstract - Secondary - Primary - Health Outcomes - NCCTG-N0147

Relationship between genetic markers and quality of life (QOL) in stage III colon cancer (CC) patients (pts) prior to adjuvant treatment (N0147).

Sloan, J. A. , Shi, Q. , Lee, A. , Diasio, R. B. , Pavey, E. S. ... - ASCO - J Clin Oncol - 2012

Abstract - Secondary-not-in-original - Primary - Health Outcomes - NCCTG-N0147

Postdiagnosis marine omega-3 fatty acid intake and survival of stage III colon cancer in North Central Cancer Treatment Group phase III trial N0147 (Alliance)

Song, Mingyang , Ou, Fang-Shu , Zemla, Tyler J. , Shi, Qian ... - DDW - Gastroenterology - 2018

Abstract - Secondary-not-in-original - Primary - GI - NCCTG-N0147

Deletions in HSP110 T17 and Patient Prognosis in Stage III Microsatellite Instable (MSI) Colon Cancers: Findings from CALGB 89803 and NCCTG N0147.

Wu, Christina , Shi, Qian , Tomsic, Jerneja , Meyers, Jeffrey ... - ASCO - J Clin Oncol - 2016

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-89803 , NCCTG-N0147

Is the predictive and prognostic impact of sporadic and familial microsatellite instable stage III colon cancer different? A pooled analysis of the PETACC8 and NCCTG N0147 (Alliance) trials

Zaanan, Aziz , Shi, Qian , Taieb, Julien , Alberts, Steven R. ... - ASCO - J Clin Oncol - 2019

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147